Form 4: Puma Biotechnology Director Troy Wilson Sells 27,000 Shares

Director Troy Wilson sold 27,000 shares of Puma Biotechnology (PBYI) common stock on June 13, 2024, at a weighted average price of $3.3297.

Summary

• On June 13, 2024, Troy Wilson, a director of Puma Biotechnology, sold 27,000 shares of common stock.
• The sale was executed under a pre-arranged 10b5-1(c) trading plan adopted on December 15, 2023.
• The shares were sold at a weighted average price of $3.3297, with individual prices ranging from $3.2801 to $3.5801.
• Following the transaction, Wilson directly owns 350 shares of Puma Biotechnology common stock.
• Wilson also indirectly owns 400 shares through Child #1 and 150 shares through Child #2.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing a stock sale by a company director. It doesn't inherently convey positive or negative sentiment, but rather provides factual information about the transaction.

Industry Context

This Form 4 filing is a routine disclosure of insider trading activity. It provides transparency into the transactions of company directors and officers, allowing investors to monitor potential alignment or misalignment of interests between management and shareholders.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies and their insiders.
• The information disclosed is consistent with regulatory requirements for reporting changes in beneficial ownership.
• Comparable companies like Seattle Genetics or Clovis Oncology would also have similar filings when their directors trade company stock.

Stakeholder Impact

• The stock sale could have a minor impact on shareholders, potentially creating slight downward pressure on the stock price in the short term.
• The sale does not appear to have a direct impact on employees, customers, suppliers, or creditors.

Key Dates